Department of Pneumology, ARRAZI Hospital, Faculty of medicine and pharmacy, Caddy Ayyad university, Mohammed VI University hospital center, Marrakech, Morocco.
Case Study
World Journal of Advanced Research and Reviews, 2024, 23(01), 3013-3017
Received on 20 June 2024; revised on 28 July 2024; accepted on 30 July 2024
Macrophage activation syndrome (MAS), also known as hemophagocytic syndrome or lymphohistiocytic activation syndrome, is a rare but potentially fatal disease. It results from inappropriate stimulation of macrophages in the bone marrow and lymphoid organs. The diagnosis of MAS is based on a combination of clinical, biological, and histological or cytological signs. MAS is categorized into primary forms, which mainly affect newborns and infants with a family history, and secondary forms, which occur in the context of neoplastic, autoimmune, or infectious diseases. Treatment involves addressing the specific causative agent of MAS and, in certain cases, early administration of corticosteroids and immunoglobulins. MAS is rarely associated with tuberculosis. We report the case of an immunocompetent patient presenting with miliary tuberculosis complicated by macrophage activation syndrome.
Macrophage activation syndrome; Tuberculosis; Immunosuppressants; Miliary tuberculosis; Myelogram
Preview Article PDF
Maryem Hindi, Oussama Fikri, Mohamed Amine Eddahioui, Houssam Biborchi, Mohamed Ijim and Lamyae Amro. Macrophagic activation syndrome complicating miliary tuberculosis: A case report. World Journal of Advanced Research and Reviews, 2024, 23(1), 3013-3017. Article DOI: https://doi.org/10.30574/wjarr.2024.23.1.2298